Details of the Drug Reposition

General Information of This Drug (ID: DMHZV7X)

• Drug Name: Golimumab (DMHZV7X)
• Synonyms: Simponi (TN); Golimumab (USAN/INN)
• Drug Type: Antibody

Information on Drug Reposition of This Drug

3 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ulcerative colitis	DIS8K27O	DD71	Approved	[1]
Rheumatoid arthritis	DISTSB4J	FA20	Approved	[2]
Psoriatic arthritis	DISLWTG2	FA21	Approved	[3]

1 Phase 2/3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Inflammatory bowel disease	DISGN23E	DD72	Phase 2/3	[4]

1 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ankylosing spondylitis	DISRC6IR	FA92.0	Discontinued in Phase 1	[5]

References

• [1] Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170.
• [2] ClinicalTrials.gov (NCT02390700) Observational Study of Golimumab Intravenous Infusion
• [3] Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6776).
• [5] Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis